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Abstract
Background: To date there has been no large-scale international study that examined the use of clozapine in older patients
with schizophrenia. This study examined the use of clozapine and its demographic and clinical correlates in older patients
with schizophrenia in East Asia during the period between 2001 and 2009.
Method: Information on 1,157 hospitalized patients with schizophrenia aged 50 or older in five East Asian countries and
territories (China, Hong Kong, Korea, Singapore and Taiwan) was extracted from the database of the Research on Asian
Psychotropic Prescription Patterns (REAP) project. Socio-demographic and clinical characteristics and prescription of
psychotropic medications were recorded.
Results: Clozapine was prescribed for 20.6% of the pooled sample; 19.0% in 2001, 19.4% in 2004 and 22.9% in 2009. Multiple
logistic regression analysis of the whole sample revealed that patients taking clozapine had a longer duration of illness,
more negative symptoms and were less likely to receive first generation antipsychotic and anticholinergic drugs, but more
likely to report weight gain compared to those not receiving clozapine. Compared to those in other sites, older patients in
China were more likely to receive clozapine.
Conclusions: The prescription of clozapine for older Asian schizophrenia inpatients has remained at a stable level during the
past decade. The appropriateness of use of clozapine in China needs to be further explored.
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Introduction
In the past two decades a number of second-generation
antipsychotic medications (SGAs) have been developed. To date
there is no clear evidence that SGAs are more effective than FGAs
in treating schizophrenia [1] apart from clozapine which is still the
most effective antipsychotic drug for treatment-resistant schizo-
phrenia [2]. In the past decades, prescribing patterns of clozapine
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have been extensively reported in patients with adult schizophre-
nia. In addition to its efficacy and side effects, different socio-
economic situations, health care policies, prescribing traditions
and clinicians’ and patients’ attitudes towards clozapine have
influenced its prescription patterns across countries [3]. For
example, clozapine was not available in Japan until the end of
2009, while in China it was one of the most commonly used
antipsychotics in the past two decades (42.2% and 34.9% of
schizophrenia inpatients and outpatients, respectively) [4].
Although their life expectancy is still significantly worse than
that of the general population [5], nowadays, with the general
improvement of psychiatric and medical care, many patients with
schizophrenia live into older adulthood. In contrast to younger
adults, psychotropic drug prescription for older patients must
consider age-related changes in drug absorption, metabolism, and
excretion and medical comorbidity. Thus, prescription patterns of
clozapine observed in younger adult patients may not reflect the
situation in patients with advanced age. We could not find a large-
scale international study that examined the use of clozapine in
older patients with schizophrenia. In order to rationalize clozapine
use, it is important to understand its prescription patterns in
clinical practice.
In most East Asian countries, community-based psychiatric care
is not well developed and hospital-based services still dominate
psychiatric care [6]. Initiated in 1999, the Research on Asian
Psychotropic Prescription Pattern (REAP) project is an ongoing
pharmaco-epidemiological survey on prescription trends of
psychotropic drugs in schizophrenia inpatients in Asia [7,8]. This
report is based on a secondary analysis of the data of the REAP
project, which was designed to: (1) examine the prescribing pattern
of clozapine in Asian schizophrenia patients aged 50 years and
above during the period between 2001 and 2009; and (2) explore
its demographic and clinical correlates. Considering the poorer
general health status of older patients, their increased vulnerability
to side effects [9,10] and the 10–15% of schizophrenia patients
who are not fully responsive to FGAs [11], we hypothesized that
the proportion of older Asian schizophrenia patients receiving
clozapine would be less than 15%. For the purpose of this study,
we defined ‘common use of clozapine’ as a figure of more than
15% in a schizophrenia patient population.
Methods
Settings, study design, and subjects
The first two surveys of the REAP project were conducted in
July 2001 and July 2004, while the data for the third one were
collected between October 2008 and March 2009. The partici-
pating countries and territories included mainland China (China
hereafter), Hong Kong, Japan, Korea, Singapore and Taiwan;
centres in India, Malaysia, and Thailand joined the surveys in
2009. Hospitals were selected according to convenience in the
participating countries/regions. Details of the REAP project have
been described elsewhere [6]. In this study, data of patients who
met the following criteria in the REAP projects were analyzed: (1)
a diagnosis of ICD-10 or DSM-IV schizophrenia, (2) being 50
years or older [12], (3) receiving antipsychotic treatment, and (4)
having the ability to understand the study, and being willing and
able to provide written or oral consent according to the
requirements of the clinical research ethics committees in the
respective study sites. Patients with major medical conditions were
excluded.
In the REAP surveys, eligible patients were enrolled consecu-
tively at each site. Socio-demographic and clinical information
including age, gender, ethnicity, the type and dose of antipsychotic
medications, benzodiazepine (BZD) and anticholinergic (ACM)
drugs, length of illness, psychopathology (positive symptoms:
hallucinations, delusions and thought disorder; negative symp-
toms: affective flattening, alogia and avolition) in the past month,
extrapyramidal symptoms (EPS; including rigidity, akinesia,
tremor, akathisia and dystonia) and weight gain within the past
three months were collected by a review of medical records in
2001, and by either the same method or patient interviews in both
2004 and 2009 using a form designed for the study. Tardive
dyskinesia (TD) is treated separately from the other forms of EPS
because of its treatment characteristics. The data were collected by
the patients’ attending psychiatrists or by members of the research
team with the agreement of the patients’ treating psychiatrists.
A total of 6,761 schizophrenia inpatients were recruited in the
three surveys; 2,399 from 31 psychiatric institutions, 2,136 from
25, and 2,226 patients from 50 in the 2001, 2004, and 2009
surveys, respectively. Altogether 2,236 patients fulfilled the above
criteria for this report. There were only 15 patients in India, 14 in
Malaysia and 8 in Thailand; in addition, in Japan clozapine was
not available during the survey period. Therefore these four sites
were excluded and thus 1,157 patients were included in the
analyses; 405 in 2001, 319 in 2004 and 433 in 2009. In order to
compare clozapine use between the current sample and younger
adult patients (i.e., those under the age of 50 years) in the REAP
project, figures of clozapine prescription in younger adult patients
are also presented.
The study protocol was approved by the clinical research ethics
committees of Chinese University of Hong Kong, Hong Kong;
Peking University Institute of Mental Health, China; Taipei City
Hospital, Taiwan; Chang Gung University, Taiwan; National
University of Singapore, Singapore; Institute of Mental Health,
Singapore; C.S.M. Medical University UP, India; National Seoul
Hospital, Korea; Prince of Songkla University, Thailand; Kuala
Lumpur Hospital, Malaysia; Seinan Gakuin University, Japan.
Given the anonymous nature of this observational study and the
minimal risk to patients, informed consent was deemed unneces-
sary in some study sites in line with the requirements of the local
clinical research ethics committee if only a review of case notes was
used. All patients receiving the interview provided written or oral
consent according to the requirements of the Clinical Research
Ethics Committee in the respective study sites.
Statistical analysis
The data were analyzed using SPSS 19.0 for Windows.
Comparisons of clozapine use between the three surveys were
performed with chi-square test. Multiple logistic regression analysis
with the ‘‘Enter’’ method was used to determine the demographic
and clinical variables independently influencing clozapine use.
Cross sectional use of clozapine was the dependent variable, while
independent variables included study sites and time, age, gender,
psychopathology, length of illness, use of FGAs, BZD and ACM,
EPS and TD. The level of significance was set at 0.05 (two-tailed).
Results
Of the 1,157 older adult patients who met study criteria, 238
(20.6%) received clozapine: 77 (19.0%) in 2001, 62 (19.4%) in
2004 and 99 (22.9%) in 2009. There was no difference between
the three surveys (x2 = 2.2, df = 2, p = 0.33). In contrast, 21.6%
(747/3,461) of younger adult patients in the REAP project
received clozapine: 20.2% (271/1,343) in 2001, 23.0% (278/
1,209) in 2004 and 21.8% (198/909) in 2009. There was no
significant difference in terms of prescription patterns of clozapine
between the two age groups in general (x2 = 0.5, df = 1, p = 0.47),
Use of Clozapine in Treatment of Schizophrenia
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or at each survey (in 2001: x2 = 0.3, df = 1, p = 0.61; in 2004: :
x2 = 1.8, df = 1, p = 0.17; in 2009: : x2 = 0.2, df = 1, p = 0.66).
Figure 1 depicts the use of clozapine in older schizophrenia
patients. Table 1 shows the socio-demographic and clinical
characteristics and the use of clozapine in the whole sample and
separately for patients by study sites.
Table 2 presents independent demographic and clinical
correlates of clozapine prescription in older schizophrenia patients.
Patients taking clozapine had longer length of illness, more
negative symptoms and were less likely to receive FGAs and ACM,
but more likely to report weight gain compared to those not
receiving clozapine.
Figure 1. Percentage of older patients with schizophrenia receiving clozapine.
doi:10.1371/journal.pone.0066154.g001
Table 1. Socio-demographic and clinical characteristics of older Asian patients with schizophrenia in REAP surveys 2001–2009.
China (n=413)
Hong Kong
(n =75) Korea (n =238)
Singapore
(n =150)
Taiwan
(n =281) Total (n = 1157)
N % N % N % N % N % N %
Age group (yrs)
50–59 339 82.1 48 64.0 181 76.1 99 66.0 217 77.2 884 76.4
60–69 62 15.0 20 26.7 51 21.4 46 30.7 46 16.4 225 19.4
70 and older 12 2.9 7 9.3 6 2.5 5 3.3 18 6.4 48 4.1
Length of illness (.5 yrs) 374 90.6 69 92.0 227 95.4 137 91.3 265 94.3 1072 92.7
Men 233 56.4 41 54.7 124 52.1 81 54.0 168 59.8 647 55.9
Presence of positive symptoms 209 50.6 53 70.7 164 68.9 73 48.7 190 67.6 689 59.6
Presence of negative symptoms 287 69.5 45 60.0 125 52.5 52 34.7 163 58.0 672 58.1
Presence of EPS 69 16.7 44 58.7 72 30.3 19 12.7 108 38.4 312 27.0
Presence of TD 17 4.1 14 18.7 17 7.1 6 4.0 33 11.7 87 7.5
On FGA 1 163 39.5 37 49.3 174 73.1 123 82.0 124 44.1 621 53.7
On non-clozapine SGA 2 64 15.5 17 22.7 47 19.7 6 4.0 49 17.4 183 15.8
On ACM 151 36.6 39 52.0 132 55.5 108 72.0 155 55.2 585 50.6
On BZD 54 13.1 18 24.0 100 42.0 68 45.3 71 25.3 311 26.9
Weight gain 29 7.0 11 14.7 12 5.0 0 0 25 8.9 77 6.7
On clozapine 168 40.7 6 8.0 6 2.5 3 2.0 55 19.6 238 20.6
1any use of FGA;
2any use of SGA; CPZeq = chlorpromazine equivalents; EPS = extrapyramidal symptoms; TD= tardive dyskinesia; FGA= first-generation antipsychotic; SGA= second-
generation antipsychotic; ACM= anticholinergic medication; BZD=benzodiazepine.
doi:10.1371/journal.pone.0066154.t001
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Discussion
In this study, prescription patterns of FGAs and SGAs varied
greatly across participating countries/regions (for details see Xiang
et al. [13]). Our hypothesis that the proportion of older Asian
schizophrenia patients receiving clozapine would be less than 15%
was not confirmed. The frequency of clozapine use in the pooled
sample of older patients was 20.6%, varying from 19.0% to 22.9%
across surveys; the results are similar to the corresponding figures
in patients under the age of 50 years in the REAP project (21.6%
in the pooled sample, varying from 20.2% to 23.0% across
surveys). It is noteworthy that there were great variations in
clozapine use between the participating sites. The frequency of
clozapine prescription was 40.7% in China and ranged between
2.5–19.6% in the other sites. The high frequency of clozapine
prescription in older Chinese patients could be explained by the
following reasons: (1) clozapine has continuously been used in
China since its introduction in 1976 with regular blood monitoring
and it has become one of the most frequently used antipsychotic
drugs in China, even as the first-line treatment in some areas [14],
yielding extensive clinical and research experience [3]; (2)
clozapine is cheap in China costing approximately US$0.08 for
300 mg; and (3) only clozapine and risperidone were covered by
basic public health insurance in most areas of China before 2005.
The gradually decreasing trend of clozapine use in China (44.8%
in 2001, 40.2% in 2004 and 37.2% in 2009; x2 = 1.8, df = 2,
p = 0.42), could be due to the introduction of strict guidelines for
clozapine use and the increasing use of other SGAs. The reasons
for the increased use of clozapine in 2009 in Singapore and
Taiwan are unknown.
Clozapine should be used in patients unresponsive to other
antipsychotic drugs [3,15], which could explain the association of
clozapine use and longer duration of illness. As negative symptoms
are far more difficult to treat, they tend to occur more frequently
in treatment-resistant schizophrenia. The recommended use of
clozapine in this population [16] may explain the association
between clozapine and negative symptoms.
In this study, adjunctive FGAs were used less frequently in the
clozapine group, which is in line with current recommendations
[17,18]. There is no compelling evidence suggesting the superi-
ority of such combinations [19]; furthermore, polypharmacy could
increase the risk of adverse effects and makes it difficult to gauge
which drug really works [20,21]. People on clozapine were less
likely to receive concurrent ACMs compared to non-clozapine
users. This represents rational practice due to the doubtful
effectiveness and elevated risk of adverse effects accompanying
such co-prescription [19]. As expected, clozapine was associated
with more weight gain in this study, which supports the findings of
previous studies [22].
The results of this survey should be interpreted with caution due
to several limitations. First, the REAP project only focuses on
inpatients in selected East Asian countries and regions. The
restriction of the study sample to hospitals selected according to
convenience where patients were consecutively examined limits
generalizability of the findings. In addition, the number of patients
on clozapine was very small in some participating countries/
regions, which hinders within-group comparisons between the
three surveys in each site. Second, the severity of psychopathology
and the drug-induced side effects were not assessed by standard-
ized instruments. Third, the data were collected by a review of
medical records in 2001 and by either a review of medical records
or patient interviews in 2004 and 2009, which might have
potentially led to observational bias. Fourth, some important
factors likely to influence appropriate clozapine use, such as age of
onset, use of prior antipsychotics, local prescription guidelines,
reimbursement policies and the type of psychiatric facilities were
not evaluated. There are differences in healthcare schemes,
prescribing traditions and treatment guidelines between institu-
tions even within one country, and within one institution between
different study times. The confounding effects of these differences
and the potential multiple interactions between them could not be
explored. More advanced analyses are needed using a sophisti-
cated design in future REAP surveys. Finally, the appropriateness
of clozapine use could not be explored.
In conclusion, one fifth of older Asian schizophrenia inpatients
received clozapine over the period between 2001 and 2009.
Clozapine was particularly commonly prescribed in China
(40.7%). Given that most treatment guidelines for schizophrenia
suggests clozapine only in treatment-resistant patients [3,16] and
considering the poorer general health status of older patients and
their increased vulnerability to psychotropic-induced side effects,
the reasons for common use of clozapine in older patients in China
warrant further investigations.
Table 2. Demographic and clinical correlates independently
associated with clozapine in the combined sample (n = 1,157).
P value
Odds
ratio 95% C.I.
Age (year)
50–59 – 1.0 –
60–69 0.21 0.7 0.4, 1.2
70 and older 0.06 0.4 0.1, 1.05
Length of illness (.5years) 0.002 3.6 1.6, 7.8
Male sex 0.85 1.0 0.7, 1.4
Positive symptoms 0.80 1.1 0.7, 1.6
Negative symptoms 0.04 1.5 1.03, 2.3
EPS 0.98 1.0 0.6, 1.6
TD 0.81 1.1 0.5, 2.3
On FGA ,0.001 0.2 0.1, 0.3
On BZD 0.06 0.6 0.4, 1.01
On ACM ,0.001 0.3 0.2, 0.5
Weight gain 0.008 2.4 1.3, 4.6
Study sites
China – 1.0 –
Hong Kong ,0.001 0.1 0.05, 0.3
Korea ,0.001 0.1 0.03, 0.2
Singapore ,0.001 0.1 0.03, 0.3
Taiwan ,0.001 0.4 0.3, 0.6
Study time
2001 survey – 1.0 –
2004 survey 0.16 0.7 0.4, 1.2
2009 survey 0.08 0.7 0.4, 1.05
Multiple logistic regression analysis with the non-clozapine group as the
reference.
There was co-linearity between the use of FGA and non-clozapine SGAs,
therefore use of non-clozapine SGA was not included in the multiple logistic
regression analysis. CPZeq = chlorpromazine equivalents; EPS = extrapyramidal
symptoms; FGA= first-generation antipsychotics; ACM=anticholinergic
medication; BZD=benzodiazepine.
doi:10.1371/journal.pone.0066154.t002
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